Holen Sie sich die Stockscreener-App
1.695
1.80%
0.025
Schlusskurs vom Vortag:
$1.67
Offen:
$1.67
24-Stunden-Volumen:
146.58K
Relative Volume:
0.39
Marktkapitalisierung:
$206.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.5415
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
-12.82%
1M Leistung:
+16.44%
6M Leistung:
-15.84%
1J Leistung:
-45.16%
1-Tages-Spanne:
$1.65
$1.73
1-Wochen-Bereich:
$1.65
$2.1591
52-Wochen-Spanne:
$1.33
$3.32
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
(302) 295-3800
Adresse
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.70 | 202.52M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.67 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.37 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.75 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.69 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
How Inhibikase Therapeutics Inc. stock performs in weak economyMarket Weekly Review & Technical Entry and Exit Tips - ulpravda.ru
Is Inhibikase Therapeutics Inc. stock attractive for passive investorsPortfolio Update Report & Weekly Watchlist of Top Performers - ulpravda.ru
Can Inhibikase Therapeutics Inc. stock sustain institutional interestJuly 2025 PostEarnings & Stepwise Trade Execution Plans - ulpravda.ru
Why Inhibikase Therapeutics Inc. stock attracts global investors2025 Sector Review & High Accuracy Swing Entry Alerts - ulpravda.ru
How Inhibikase Therapeutics Inc. (IQT0) stock reacts to stronger dollarWeekly Loss Report & Safe Entry Point Identification - ulpravda.ru
Can Inhibikase Therapeutics Inc. (IQT0) stock surprise with quarterly results2025 Key Lessons & Low Drawdown Trading Strategies - ulpravda.ru
Published on: 2026-01-08 18:28:15 - ulpravda.ru
What analyst consensus says on Inhibikase Therapeutics Inc. stockGap Up & Safe Swing Trade Setup Alerts - ulpravda.ru
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Is Inhibikase Therapeutics Inc. stock attractive for income investorsHealthcare Stock Analysis & Budget Investment Success - ulpravda.ru
Laser Focus WorldInhibikase Therapeutics, Inc.Common Stock (Nasdaq:IKT) Stock Quote - FinancialContent
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Critical Survey: Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics (IKT): HC Wainwright & Co. Issues 'Buy' Rating | IKT Stock News - GuruFocus
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) price target decreased by 20.00% to 5.71 - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN
Contrasting Inhibikase Therapeutics (NYSE:IKT) and Sorrento Therapeutics (NASDAQ:SRNE) - Defense World
Is Inhibikase Therapeutics Inc. stock a safe buy before earningsOptions Trading Strategies & Low Risk Trading Growth - bollywoodhelpline.com
Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Contrast - Defense World
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Can Inhibikase Therapeutics Inc. stock double in next 5 years2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - Улправда
Gains Report: Why Inhibikase Therapeutics Inc. stock remains a top recommendationEarnings Summary Report & Low Risk High Reward Trade Ideas - moha.gov.vn
Will Inhibikase Therapeutics Inc. stock sustain high P E ratios2025 Market Sentiment & Growth Focused Stock Reports - Улправда
Inhibikase Updates ATM Equity Program to Raise Capital - The Globe and Mail
Inhibikase Therapeutics Earnings Notes - Trefis
Inhibikase Therapeutics Updates ATM Offering Program - TradingView — Track All Markets
Is Inhibikase Therapeutics Inc. stock recession proofJuly 2025 Sentiment & Safe Entry Trade Signal Reports - DonanımHaber
Why Inhibikase Therapeutics Inc. stock remains a top recommendationQuarterly Performance Summary & Momentum Based Trading Signals - DonanımHaber
Dow Update: Is Inhibikase Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Big Picture & Reliable Volume Spike Alerts - Улправда
What drives Inhibikase Therapeutics Inc stock priceVolume Weighted Average Price & Free Stock Index Interpretations - earlytimes.in
While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald - MarketBeat
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) & Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg - GuruFocus
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT) - MarketBeat
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Zacks Research - MarketBeat
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):